The aim of this study was to investigate the putative link between dipeptidyl peptidase-4 inhibitor (DPP-4i) use and the risk of fracture in patients with type 2 diabetes.
Introduction
Patients with type 2 diabetes mellitus have increased risks of osteoporosis, bone fragility, and even bone fractures [1, 2] . Among such patients, bone fractures are usually triggered by recurrent falls [3] caused by diabetes-related comorbidities such as retinopathy, loss of balance, neuropathy and hypoglycaemic events [1, 4, 5] , as well as hyperglycaemiainduced alterations in the tissue-matrix composition. Glucose-lowering medications such as thiazolidinedione have been reported to reduce bone density [6, 7] and increase the risk of fracture [8, 9] . A recent large-scale study integrated data from two trials and proposed that canagliflozin, a sodium-glucose cotransporter 2 inhibitor, could increase the risk of fracture [10] . In addition, despite its neutral effect on bone density [11] , insulin therapy is associated with an increased fracture risk [12] [13] [14] .
The pharmacological target of dipeptidyl peptidase-4 (DPP-4) is part of the prolyl oligopeptidase family [15] . DPP-4 is well known for its role in glucose homeostasis and has become a validated therapeutic target for the treatment of type 2 diabetes [16] . DPP-4 inhibitors (DPP-4is) reduce the rate of GLP-1 inactivation and are a relatively new antihyperglycaemic drug that has been on the market since 2006 [17] . Since then, five DPP-4i drugs have received coverage from Taiwan National Health Insurance: sitagliptin on 1 March, 2009; saxagliptin on 1 March, 2011; vildagliptin on 1 August, 2011; linagliptin on 1 June, 2012; and alogliptin on 1 November, 2015. Two other drugs belonging to this class, teneligliptin and anagliptin, have not receive marketing authorization in Taiwan. DPP-4is might influence bone metabolism, potentially reducing fracture risk [18] . A meta-analysis of randomized controlled trials (RCTs) showed a reduced fracture risk in DPP-4i users [19] . Similarly, a previous study demonstrated that the serum levels of total alkaline phosphatase and urinary deoxypyridinoline considerably decreased in postmenopausal women with diabetes who received 12 weeks of sitagliptin therapy [20] . By contrast, other meta-analyses of RCTs revealed no significant associations between fracture events and DPP-4i use compared with placebo or active comparator use [21, 22] . Moreover, a series of observational studies found no associations between DPP-4i use and fracture risk [23] [24] [25] [26] .
In addition to inconsistency in the findings of previous studies, one major limitation of observational studies and RCTs is that the actual duration of DPP-4i use might be too short to reveal a real association between DPP-4i use and fracture risk [19, 23, 24] . The longest recorded follow-up period for DPP-4i use is only 1.6 years [25] . In some observational studies, fracture was not the primary endpoint and data on fractures were not routinely collected [23, 24, 27] . Moreover, some meta-analyses have combined heterogeneous comparison groups characterized by different ages, sexes and sites of fracture [19, 22] . However, the incidence rates of fractures are different for men and women, and the disease burden of fractures increases with age [28] . A previous meta-analysis suggested that thiazolidinediones caused differing bone fracture incidence rates for men and women and that the fracture risk associated with thiazolidinediones increases with age [29] . Additionally, another study also showed that the fracture risk associated with thiazolidinediones differed depending on the fracture site, especially in older patients [30] . Despite this data, no studies had attempted to measure the potential effects of age and sex on DPP-4i use and the risk of fracture.
Because of contradictory evidence and a lack of information concerning the incidence rates of fractures after long-term DPP-4i use [19, 23, 24] depending on age, sex and fracture site, we conducted the current five-year populationbased cohort study to elucidate the relationship between DPP-4i use and fracture risk. In addition to overall fracture risk, we investigated site-specific fracture risk associated with DPP-4i use.
Methods

Data source
In this study, we analysed the medical claims data of the Longitudinal Cohort of Diabetes Patients (LHDB) from 1999 to 2013. The data were retrieved from the Taiwan National Health Insurance Research Database (NHIRD). Details of the LHDB were reported in our earlier study [31] . Briefly, the LHDB consists of a sample of 120 000 incident cases of diabetes (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 250.xx) between 1999 and 2013. These patients were randomly selected from all patients with diabetes who are covered by the National Health Insurance program (NHIP), a mandatory-enrolment, single-payment, state-run system that covers more than 99% of Taiwan's population. In our study, in order to be considered a patient with diabetes, an individual must meet at least one of the following three criteria: (1) two or more ambulatory care visits with a diagnosis of diabetes within 1 year; (2) one ambulatory care visit with a diagnosis of diabetes and prescription of antidiabetic drugs within 1 year; and (3) one or more hospitalizations with a discharge diagnosis of diabetes or prescription of antidiabetic drugs within 1 year [32, 33] . Because the NHIP was implemented in 1995, the LHDB excludes patients diagnosed with diabetes before 1999 to ensure that only incident cases of diabetes are included. In total, 1 197 371 patients with diabetes were initially identified.
This study was approved by the Institutional Review Board of National Cheng Kung University Hospital, who granted a waiver from obtaining informed consent from individual patients because the patients in the database analysed, the NHIRD, were de-identified (Approval No. A-ER-103-298).
Study cohort and design
We established two inclusion criteria for the study cohort based on the LHDB. First, only patients who fit the ICD-9-CM diagnosis code of 250.x0 or 250.x2 (type 2 diabetes) were included in this study. Second, patients were required to have at least three consecutive refills of metformin with an interval between any two consecutive refills of <30 days during the follow-up period. A total of 427 223 patients met these two criteria from 1999 to 2013 and were considered patients with type 2 diabetes who were stable metformin users.
Because DPP-4i use was not approved by the NHIP until 2009 [34] , we further identified patients with any second-line antidiabetic drug use during 2009-2012. In Taiwan, various DPP-4 inhibitors have been used, including sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, gemigliptin, and evogliptin. The daily dose of DPP-4i prescribed to patients with type 2 diabetes in clinical settings has ranged from 5 mg (saxagliptin and linagliptin) to 100 mg (sitagliptin). The starting date of second-line antidiabetic drug use was defined as the index date. Patients using any second-line antidiabetic drug or receiving insulin therapy within 180 days before the index date were excluded to ensure that all the study patients were new users of dual therapy (n = 53 347). To ensure the validity of the incidence rate of fracture, we further excluded patients with a history of fracture (ICD-9-CM codes 800-829) or cancer (ICD-9-CM codes 140-243) within 1 year before the index date (n = 8401). Finally, 44 946 patients were included in the study cohort.
In the study cohort, 3996 patients used a DPP-4i as a second-line antidiabetic drug, and the remaining 40 950 patients used other second-line antidiabetic drugs including sulfonylurea, acarbose, meglitinide, and thiazolidinedione. Figure 1 presents the details of study cohort enrolment.
To minimize the potential for confounding by indication, we performed one-on-one propensity score matching to select non-DPP-4 users. The matching algorithm determines first the 'best' matches and subsequently the 'next-best' matches in a hierarchical sequence until no more matches can be determined (i.e., greedy matching technique) [35] . For each study patient, the propensity score was calculated using all the variables listed in Table 1 to compare the baseline characteristics of DPP-4i users and non-DPP-4i users before and after propensity score matching. The information in Table 1 indicates that after propensity score matching, the baseline characteristics of DPP-4i users and non-DPP-4i users were fairly comparable.
Follow-up and study endpoint
For each study patient, the follow-up period started from the index date and ended on the date of event (i.e., fracture) diagnosis or censoring, which was either the date of health insurance policy termination or the final day of 2013. The followup length ranged from a minimum of 1 year (2012-2013) to a maximum of 5 years (2009-2013). The study endpoint was all-cause fracture (ICD-9-CM codes 810-829). In addition, subgroup analyses were conducted to estimate the risks of hip fracture (ICD-9-CM codes 820-821), lower extremity fracture (ICD-9-CM codes 820-829) and upper extremity fracture (ICD-9-CM codes 810-819). The study endpoint was identified through the interlinking of the study cohort to both ambulatory and hospitalization medical claims.
Covariates
The covariates considered in this study included patient age on the index date, sex and various comorbidities identified within 1 year before the index date. The comorbidities considered were fall (ICD-9-CM E codes 880-888); osteoporosis (ICD-9-CM code 733); dizziness (ICD-9-CM code 780.4); vertigo (ICD-9-CM code 386); visual impairment (ICD-9-CM codes 360-379); hyperthyroidism (ICD-9-CM code 242); parahypothyroidism (ICD-9-CM code 252); hypothyroidism (ICD-9-CM code 244); arthropathy (ICD-9-CM codes 710-719); rheumatism (ICD-9-CM codes 714 and 725-729); dorsopathy (ICD-9-CM codes 720-724); osteopathy, chondropathy and acquired musculoskeletal deformities (ICD-9-CM codes 730-732 and 734-739, respectively); joint pain (ICD-9-CM codes 713, 715, 716, 718, and 719); cancer (ICD-9-CM codes 140-239); pathological fracture (ICD-9-CM code 733.1); smoking (chronic obstructive pulmonary disease; ICD-9-CM codes 490-496); alcohol-related diseases (ICD-9-CM codes 291, 303, 305.0, and 571.0-571.3); anorexia nervosa and bulimia (ICD-9-CM codes 307 and 783); and chronic kidney disease (ICD-9-CM code 585). In addition, we calculated the Charlson comorbidity index [36] and Diabetes Complication Severity Index [37, 38] to represent each patient's comorbidity level and type 2 diabetes severity, respectively.
Statistical analysis
Patient characteristics were analysed using descriptive statistics, which included the mean, standard deviation, frequency and proportion. Baseline covariates were compared using the independent t-test or the Pearson chi-square (χ 2 ) test. The incidence rate of fractures was calculated under the Poisson assumption as the total number of people who developed fractures during the follow-up period divided by people at risk per year. The people at risk per year were calculated from the index date to the occurrence of the endpoint, NHIP termination, or the end of 2013.
A Cox proportional hazard model was used to estimate crude and covariate-adjusted hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs). We assessed the potential problem of collinearity among the covariates by examining the estimated slope coefficients and SEM and found no indication of collinearity. The proportional hazard assumption was verified using plots of log(Àlog(survival Figure 1 Flowchart of study cohort enrolment function)) vs. log(time) and Schoenfeld residuals vs. time. We found no evidence to contradict the proportionality assumption for the Cox proportional model. The significance level of all hypothesis testing was set at 0.05. SAS 9.4 software (SAS Institute, Inc., Cary, NC) was utilized for the aforementioned analyses.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [39] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [15] . Table 1 Comparison of baseline characteristics of DPP-4i and non-DPP-4i users before and after propensity score matching 
Results
The characteristics of the study population are shown in Table 1 . After propensity score matching, the distributions of age, sex, comorbidity level, severity and duration of diabetes, and selected comorbidities that predispose patients to fracture risk were comparable between DPP-4i users and non-DPP-4i users. Over a maximum follow-up period of 5 years, 340 (8.5%) DPP-4i users and 419 (10.5%) non-DPP-4i users developed fractures, corresponding to the incidence rates of 28 Table 2 ). Figure 2 compares the Nelson-Aalen cumulative hazard (event) rates of the onset of all-cause and site-specific fractures for patients receiving DPP-4i and those not. The patients receiving DPP-4i had lower event rates over the study period. Table S3 ). Nonetheless, the aforementioned sex and age differences in relation to the risks of lower and upper extremity fractures did not reach statistical significance in the multiple testing of subgroup analyses. Additional analyses were performed for head-to-head comparisons of fracture risks between patients receiving DPP-4i and those receiving other oral antidiabetes drugs individually. These data, which are presented in Supporting Information Table S4, demonstrated that patients treated with DPP-4i tended to experience consistently lower risk of all fractures and site-specific fracture compared with patients treated with other drugs except acarbose.
Table 2
Overall, age-specific, and sex-specific incidence rates and hazard ratios of all fractures (ICD-9-CM codes 800-820) in association with DPP-4i use in patients with type 2 diabetes 
Discussion
In this population-based cohort study, we discovered that DPP-4i use was significantly associated with reduced risks of all-cause and upper extremity fractures in patients with type 2 diabetes. No significant interaction was observed between DPP-4i use and age or sex, but the data did indicate the presence of a significant association between DPP-4i and a reduced risk of all fractures only in women with diabetes aged 45-54 years. However, we should conservatively interpret the results of subgroup analyses because multiple comparisons could have yielded false positive findings. Furthermore, site-specific analysis suggested that a significantly lower risk was noted only for upper extremity fractures in women, particularly those aged 55-64 years.
The aforementioned results are unlikely to have been confounded by demographic characteristics, diabetes severity or fracture-related comorbidities. To the best of our knowledge, the current study is the first age-and sex-stratified analysis to evaluate the relationship of DPP4i usage according to different fracture sites.
An earlier meta-analysis of 28 randomized clinical trials involving 11 880 and 9175 patients with DPP-4i and comparator use, respectively, found that compared with placebo or other treatments, DPP-4i use was associated with a reduced risk of fractures (odds ratio: 0.60, 95% CI: 0.37-0.99, P = 0.045) [19] . However, such a protective effect was not observed in a subsequent updated meta-analysis, which Figure 2 Comparison of Nelson-Aalen cumulative hazard estimates of the onset of (A) all fractures (ICD-9-CM codes 800-820), (B) hip fracture (ICD-9-CM codes 820-821), (C) lower extremity fracture (ICD-9-CM codes 820-829), and (D) upper extremity fracture (ICD-9-CM codes 810-819) between the DPP-4i and non-DPP-4i groups DPP-4i use fracture in type 2 diabetes patients incorporated more study participants (62 206 including 33 452 patients treated with DPP-4i) [22] . In addition to the inconsistent study findings, the durations of most trials included in the aforementioned meta-analyses were relatively short (mostly 24 months), which does not facilitate the drawing of inferences on the long-term effects of DPP-4i use on fractures. Furthermore, bone fractures were not the primary endpoints in any of the aforementioned trials and have been reported only as adverse events, which constitute only a fraction of all fractures [19, 21] .
Driessen et al. [23] conducted a retrospective populationbased cohort study by using data from the Clinical Practice Research Datalink (CPRD) database from 2007 to 2012. The researchers found that DPP4-i use was not associated with fracture risk compared with controls and other noninsulin antidiabetic drugs. However, the actual duration of DPP4-i use was only 1.3 years. In a subsequent case-control study, Driessen et al. [24] analysed the relationships between DPP4i use and various site-specific risks of fracture including hip, radius or ulna, and vertebral fractures. The researchers showed that DPP4-i use (current, recent, past or distant past) was not associated with the risk of hip fracture or radius or ulna fracture. However, although current DPP4-i use was not associated with the risk of vertebral fracture, recent DPP4-i use significantly decreased the risk of vertebral fracture [24] . Using data from the CPRD database, Driessen et al. [25] recently conducted a retrospective population-based cohort study covering a longer period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . The study reported that continuous long-term DPP-4i use (defined as >4.0-8.5 years of DPP-4i use for any fracture, >3.0-8.5 years for osteoporotic fracture, and >2.0-8.5 years for hip fracture) was not associated with the risk of any, osteoporotic or hip fracture. By contrast, a recent nationwide study in South Korea showed that DPP-4i use might exert a protective effect on composite bone metabolism [40] . However, meta-analyses of RCTs [21, 22] and observational studies [23] [24] [25] have observed no significant protective effects of DPP-4i on fracture. This discrepancy may be attributed to the potential heterogeneity in the study methodologies included in the meta-analyses or to inadequate duration of DPP4i use. Moreover, in contrast to the aforementioned real-life observational studies that have used a multivariate regression model to remove potential confounding factors [23] [24] [25] , the current study used the propensity score matching technique to select controls, which is considered relatively effective for controlling for confounding factors by indication [41] . This may have also contributed to the dissimilarity in findings between previous studies and the current study.
Because DPP-4 is an enzyme involved in the degradation of glucagon-like peptide-1, which plays a role in promoting bone formation and inhibiting bone resorption, DPP-4i may exert a beneficial effect on bone metabolism [42] [43] [44] . In an animal study [45] , the use of sitagliptin, a DPP-4i, was found to increase trabecular bone volume, cortical bone volume and bone mineral density in diabetic male rats. Sitagliptin use was also associated with the attenuation of bone strength loss and reduction of bone resorption. These findings were supported by those of another animal study [46] , where high-fat-diet-fed mice treated with sitagliptin showed an increase in vertebral bone mineral density. Moreover, a recent in vivo study showed that MK-0626, another DPP-4i, exerted neutral effects on cortical and trabecular bone in a type 2 diabetes mouse model, and MK-0626 did not alter osteoblast differentiation [47] . Thus, bone quality may be more crucial than bone density in predicting the increased risk of fracture in patients with type 2 diabetes [5] .
This study has the following strengths. First, this study adopted a large, nationwide, population-based design with high representativeness of all patients with type 2 diabetes in Taiwan during 2009-2013. The study sample size was sufficiently large for performing age-and sex-stratified analyses to investigate the potential modifiers of the effect of DPP-4i use on fracture risk without comprising statistical power. Moreover, additional analyses were performed for head-tohead comparisons of fracture risks between patients receiving DPP-4i and those receiving other oral antidiabetes drugs individually. We used the propensity score matching technique to select and pair the patients not receiving DPP-4i to each group of patients receiving oral antidiabetes drugs other than DPP-4i. The results indicated that patients receiving DPP-4i tended to experience a consistently lower risk of all fractures and site-specific fractures compared with patients receiving other drugs.
Second, in contrast to previous meta-analyses of RCTs or observational studies of which the average study duration was relatively short (mostly 24 months), the present study adopted a longer follow-up period (maximum of 5 years) to observe the occurrence of fracture events. Moreover, in contrast to many previous meta-analyses [19, 21, 22] that did not use fracture as the primary endpoint, our study was designed to specifically investigate the risk of fracture in patients with type 2 diabetes, thereby also minimizing the likelihood of type 1 error inflation. Furthermore, we calculated in years the average time period from patient enrolment to the occurrence of an all-cause fracture for patients who experienced a fracture. The average time-to-event periods for patients experiencing a fracture in the DPP-4i and non-DPP-4i groups were 1.69 and 1.87 years, respectively. Such short drug exposure periods were less likely to change the bone metabolism. Further studies of patients after a longer period of drug exposure may provide evidence concerning the long-term effect of DPP-4i on fracture. Although this analysis was limited to patients who had already developed a fracture, our results did not indicate a significant difference in the risk of or time period for a fracture occurrence between patients experiencing fractures because of falls consequent to hypoglycaemia (e.g., sulfonylureas and meglitinides) and fractures directly associated with bone metabolism (e.g., thiazolidinediones).
Third, in contrast to many previous observational studies that used clinical data from several hospitals [23] [24] [25] [26] , the present study is the first to use the insurance claims data of the entire population of a nation, thereby ensuring complete coverage of patients with type 2 diabetes or fractures. In addition to the overall fracture risk presented in the aforementioned South Korean study [40] , we further confirmed the effect of DPP-4i use on fractures by conducting subgroup analyses of fractures at various sites including hip, lower extremity and upper extremity fractures to ensure the robustness of our findings.
Fourth, the type 2 diabetes cohort in this study was recruited from the LHDB and all research information was retrieved from the medical claims data in the NHIRD, thereby minimizing the likelihood of erroneous recall of drug use, nonresponse and loss to follow-up.
Fifth, to accurately estimate the incidence of fracture, we identified patients with fracture from inpatient and outpatient settings. Finally, we used propensity score matching to select controls, thereby considerably minimizing the potential for confounding by indication.
Despite the aforementioned methodological strengths, our study has several limitations. First, diagnoses of type 2 diabetes and fractures were completely dependent on ICD-9-CM codes, which are subject to disease misclassification. This constitutes a major limitation of this study compared with studies based on information obtained from standardized clinical examinations of patients. However, the National Health Insurance Administration of the Ministry of Health and Welfare conducts quarterly expert reviews of any hospital with outlier charges or outlier practice patterns, which could effectively minimize the potential for disease misclassification.
Second, although we adjusted for certain potential confounders in the analysis, other known risk factors for fracture were not adjusted for in the analysis. These risk factors included patients' socioeconomic background, family history of fracture [48, 49] , and health behaviours (e.g., glucose control, physical activity and body mass index [50] [51] [52] . Failure to comprehensively adjust for these potential confounders may result in residual confounding at least to a certain degree. However, we further conducted falsification analyses using upper gastrointestinal (UGI) haemorrhage as a negative study endpoint. UGI was not expected to be related to DPP-4i usage. The analysis demonstrated that patients who used DPP-4i had a slightly but insignificantly lower hazard ratio (covariate-adjusted HR: 0.93 [95% CI: 0.80-1.09]) for all UGI haemorrhage. This additional analysis provided reassurance that the inverse relationship between DPP-4i use and the risk of fracture found in our study was unlikely to be entirely caused by unmeasured confounders.
Third, we did not account for the fracture risk associated with a specific DPP-4i in our study. Determining whether a dose-gradient relationship exists between DPP-4i use and fracture risk in patients with type 2 diabetes may help to elucidate the mechanism underlying the effect of DPP-4i use on fracture risk. Additionally, renal function adjustment was lacking in our study because no laboratory data were available in the NHIRD. However, we compared the numbers of DPP-4i and non-DPP-4i users before and after propensity score matching and no significant difference was observed. Subgroup analyses of drugs belonging to this class (e.g., sitagliptin, linagliptin, saxagliptin and alogliptin) would also be needed in further studies. However, we should also interpret our study results with caution because multiple comparisons with several subgroup analyses might have increased the chance of false positive findings.
Finally, the majority of our cohort was Asian; therefore, whether the results may be extrapolated to other populations (e.g., Caucasians) must be answered through further studies.
Conclusions
This population-based cohort study demonstrated that DPP4i use is significantly associated with decreased risks of all fractures and lower extremity fractures in patients with type 2 diabetes. Such a negative association was seemingly sustained across all age and sex stratifications. Although some potential mechanisms have been proposed for the putative link between DPP-4i use and the reduced risk of fracture, additional pharmacoepidemiological studies are required to provide more concrete evidence for the seemingly beneficial effect of DPP-4i use. Biological studies exploring the actual mechanisms underlying the association between DPP-4i use and the risk of fracture are also warranted.
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